New River reiterated at buy: Merrill

New River Pharmaceuticals Inc. was reiterated at buy by Merrill Lynch analysts David W. Munno, Eric J. Ende and Thomas J. McGahren. They said an Adderall XR patent settlement would benefit the company, substantially reducing the risk of earlier-than-expected generic competition. New River shares closed Thursday down $0.04, or 0.11%, at $36.96 on volume of 392,542 shares compared with a three-month trailing average of 54,862 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.